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It is widely appreciated that G protein-coupled receptors have been the most successfully exploited class of targets for the de-
velopment of small molecule medicines. Despite this, to date, less than 15% of the non-olfactory G protein-coupled receptors in
the human genome are the targets of a clinically usedmedicine. In many cases, this is likely to reﬂect a lack of understanding of the
basic underpinning biology of many G protein-coupled receptors that are not currently in the spotlight, as well as a paucity of
pharmacological tool compounds and appropriate animal models to test in vivo function of such G protein-coupled receptors in
both normal physiology and in the context of disease. ‘Open Innovation’ arrangements, in which pharmaceutical companies and
public–private partnerships provide wider access to tool compounds identiﬁed from ligand screening programmes, alongside
enhancedmedicinal chemistry support to convert such screening ‘hits’ into useful ‘tool’ compounds will provide important routes
to improved understanding. However, in parallel, novel approaches to deﬁne and fully appreciate the selectivity and mode of
action of such tool compounds, as well as better understanding of potential species orthologue variability in the pharmacology
and/or signalling proﬁle of a wide range of currently poorly understood and understudied G protein-coupled receptors, will be
vital to fully exploit the therapeutic potential of this large target class. I consider these themes using as exemplars two G protein-
coupled receptors, free fatty acid receptor 2 and GPR35.
Abbreviations
4-CMTB, (S)-2-(4-chlorophenyl)-3-methyl-N-(thiazol-2-yl)butanamide; AZ1729, N-[3-(2-carbamimidamido-4-methyl-1,3-
thiazol-5-yl)phenyl]-4-ﬂuorobenzamide; CATPB, (S)-3-(2-(3-chlorophenyl)acetamido)-4-(4-(triﬂuoromethyl)phenyl)
butanoic acid; DREADD, designer receptor exclusively activated by designer drug; GLPG0974, 4-[[1-(benzo[b]thiophene-3-
carbonyl)-2-methylazetidine-2-carbonyl]-(3-chlorobenzyl)amino]butyric acid; SCFA, short-chain fatty acid
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Introduction
Introductory remarks in many publications and grant appli-
cations that centre on aspects of the pharmacology, function
or therapeutic potential of members of the GPCR superfam-
ily highlight both the historical and ongoing success of
targeting GPCRs for the development of medicines to treat
human diseases. This undoubtedly reﬂects the very broad
range of physiological end points controlled by GPCR
activity and the relative ease of targeting small molecule
(low MW) drugs to interact with proteins located predomi-
nantly at the external surface of cells. The central roles that
neurotransmitters such as noradrenaline, 5-HT and dopa-
mine play in, for example, cardiovascular and neuronal
functions, and the potential for dysregulation of these
systems in highly prevalent disease states have resulted in a
plethora of medicines targeting GPCRs that are activated by
such biogenic amines and recognition of the life-changing
beneﬁts such drugs produce. However, many other GPCRs
have not been studied in anywhere near the level of detail
as those that respond to biogenic amines, and only in the
region of 15% of the non-olfactory GPCRs are the target of
one or more clinically approved small molecule medicine.
There are many reasons for this. With more than 350 non-
olfactory GPCRs in the human genome (Alexander et al.,
2015a) it is clear that a substantial number must play more
modulatory and subtle roles than those activated by the key
biogenic amines. As such, alterations in their function may
be more difﬁcult to assess, particularly when ‘disease’ has
frequently been considered in the context of animal models
that have less than perfect correlation with human disease
states. Furthermore, despite many years of effort, endoge-
nously produced ligands that activate more than 100 of the
non-olfactory GPCRs remain unidentiﬁed or, at least,
suggested endogenous ligands for many of these remain to
be broadly accepted and agreed on by the research commu-
nity. Such GPCRs are deﬁned as ‘orphans’ (Alexander et al.,
2015a). This is further complicated by frequent lack of repro-
ducibility between reports. For example, although the
‘orphan’ receptor GPR17 has been reported to respond to
uracil nucleotides and cysteinyl leukotrienes (Ciana et al.,
2006), this has been disputed by others (Qi et al., 2013; Simon
et al., 2017).
An additional reason for the current lack of small mole-
cule medicines that target certain GPCRs is that in a number
of examples of GPCRs that are activated by large peptide
hormones, medicines to treat disease are based on the activat-
ing peptide itself, or on ways to prevent degradation of the
peptide. This often reﬂects a broad ranging lack of success to
date in identifying tractable starting points for small
molecule activators of these GPCRs rather than a lack of
conﬁdence that stimulating the GPCR in question with such
a ligand would have clinical beneﬁt. Indeed, in the case of the
glucagon-like peptide 1 (GLP-1) receptor, peptides
related to GLP-1 or inhibitors of dipeptidyl peptidase-4,
the enzyme that degrades GLP-1, are already effective
therapeutic agents. There are also examples where clinical
proof-of-concept has been produced but side effects or
toxicity of the ligand tested has prevented its further develop-
ment. A recent example was the withdrawal from phase III
clinical trials of the free fatty acid FFA1 receptor agonist
TAK-875/fasiglifam. This not only produced effective
lowering of blood glucose levels and of glycated haemoglobin
in patients with Type 2 diabetes but also induced liver
toxicity by inhibiting a number of bile acid transporters
(Kaku et al., 2015, 2016). Such late-stage failures in clinical
studies, even if they may be related more to the speciﬁc
molecule that was trialled rather than issues related more
generally to the speciﬁc GPCR targeted, understandably
result in considerable caution in further efforts to revisit such
a target (Ghislain and Poitout, 2017; Suckow and Briscoe,
2017). However, a major issue for many molecules that have
entered clinical trials, beyond potential toxicity, has been
that they prove to lack efﬁcacy in the disease state targeted.
This can be the case even when various biomarker signatures
provide support for appropriate target engagement for the
ligand (see Pizzonero et al., 2014; Namour et al., 2016). As
such, a more broad reaching issue which may be hindering
progress towards novel medicines that function at previously
non-targeted GPCRs may be a lack of understanding of the
basic biology and connectivity of systems controlled and
their direct link to human disease. This can also be reﬂected
in marked variability in the pharmacology of species
orthologues of a number of poorly studied GPCRs that limits
understanding of the function of such receptors in animal
models (Figure 1).
I addressed a number of these issues within a Symposium
on “Non-traditional/Orphan GPCRs as therapeutic targets”
held during the Pharmacology 2016 meeting in London,
and the current review centres on topics considered in that
presentation.
GPCR de-orphanization and the
development of medicines
Particularly within the pharmaceutical industry, during the
1990s and 2000s, there was a drive to identify cognate ligands
for many previously ‘orphan’ GPCRs. This reﬂected the
widely held view that many more GPCRs would be deﬁned
as therapeutic targets if a much clearer understanding could
be obtained of the endogenously produced ligands that acti-
vate them. This was further promoted if genetic elimination
of the receptor orthologue in mice generated a distinct and
clearly observed phenotype (Wise et al., 2004; Civelli et al.,
2013). Some clear successes have emerged from this strategy.
However, as with other medicine development programmes,
the period between project initiation and drug agency ap-
proval has been extensive. An outstanding example has been
identiﬁcation of a pair of orphan GPCRs, now designated
OX1 and OX2 receptors, as the partners for the neuropep-
tides orexin A and orexin B. Although initially suggested
to play important roles in stimulation of appetite and to
affect energy metabolism, which suggested potential as
therapeutic targets in obesity and control of weight gain,
further studies demonstrated a key role for the orexins in
the stabilization of wakefulness. Linked to the identiﬁcation
of inactivating mutations associated with narcolepsy within
the OX2 receptor in dogs, this provided the drive to target
these receptors in sleep disorders. While either selective OX2
or dual OX1/OX2 agonists could, therefore, be considered as
potential treatments for human narcolepsy, little progress
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appears to have been made to date in efforts to identify low
MW agonists of these receptors. However, lowMWOX recep-
tor antagonists were readily identiﬁed, and subsequently, this
led to the development of suvorexant, a dual OX1/OX2
antagonist, which has been approved for treatment of insom-
nia (Norman and Anderson, 2016).
Other effective de-orphanization efforts have not (yet) re-
sulted in the development and approval of novel medicines,
despite clear validation of the target GPCR and enormous
commitment. One of the most effective means to regulate
favourably blood lipid levels and composition is treatment
with niacin (also known as nicotinic acid) (Gille et al.,
2008). Niacin acts as an anti-lipolytic agent at white fat cells
and, therefore, reduces entry of stored lipids into the blood-
stream. Moreover, early studies had indicated that it must
do so via activation of a Gi-coupled GPCR. Identiﬁcation of
a receptor or receptors for niacin thus focused on a group of
orphan GPCRs expressed in adipocytes. Following selection
of 10 such orphan GPCRs Wise et al. (2003) screened each
of these and demonstrated that niacin was able to increase
binding of [35S]GTPγS in membranes prepared from cells
transfected to express the receptor HM74. Two other
closely related receptors HM74a and GPR81 were also able
to allow a high concentration of niacin to enhance binding
of [35S]GTPγS. Further studies showed the potency of nia-
cin to be markedly higher at HM74a compared to HM74,
with only very low potency observed at GPR81 (Wise
et al., 2003). IUPHAR consolidation and rationalization of
nomenclature have resulted in HM74a now being desig-
nated hydroxycarboxylic acid receptor 2 (Offermanns
et al., 2011). A marked side-effect of treatment with niacin
is the development of cutaneous vasodilatation, or ﬂush-
ing, on the chest and face. This markedly affects patient
compliance in maintaining the treatment. As it was sug-
gested that the ﬂushing effects of niacin treatment might
be separable from the lipid-modifying effects, because the
beneﬁcial effects appeared to be G protein-mediated whilst
ﬂushing appeared to be arrestin-dependent, then efforts to
identify and develop G protein-‘biased’ agonists at this
receptor have been made (Shen et al., 2010; Kim et al.,
2015). However, these have not translated into clinical
trials, and currently, although much discussed and studied,
no GPCR ligand developed speciﬁcally with the concept
that signalling ‘bias’ might provide distinct clinical beneﬁts
compared to non-biased ligands at the same receptor has
yet received regulatory approval. However, oliceridine
(TRV130), a somewhat G protein-biased agonist at the
μ-opioid receptor, is currently undergoing clinical trials
for pain relief (Viscusi et al., 2016).
Understanding the function of GPCRs
that are not currently in the spotlight
GPCRs for biogenic amines, and for other transmitters such
as acetylcholine, have been and remain the most studied
Figure 1
Many GPR35 agonists display markedly different potency at human and rodent orthologues. Representative concentration–response curves for
four ligands with agonist potency at GPR35 are shown. All experiments reﬂect ligand-induced interactions between transiently co-expressed
forms of β-arrestin-2 and the indicated species orthologue of GPR35. For human GPR35, the short isoform (GPR35a) was used, which corresponds
to the single form of GPR35 expressed by rat and mouse. Zaprinast displays modest but similar potency at each orthologue, whilst each of
lodoxamide, pamoic acid and ‘compound 1’ (4-{(Z)-[(2Z)-2-(2-ﬂuorobenzylidene)-4-oxo-1,3-thiazolidin-5-ylidene]methyl}benzoic acid) are
markedly more potent at human GPR35 than at mouse GPR35 and, as such, are inappropriate to explore functions of the mouse orthologue. Data
are adapted from Jenkins et al., 2010, Neetoo-Isseljee et al., 2013 and Mackenzie et al., 2014.
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family members. In part, this reﬂects a cycle of productivity.
As among the ﬁrst cloned members of the GPCR superfamily,
they were the ﬁrst to be expressed in heterologous systems
and, apart from the photon receptor rhodopsin, the ﬁrst for
which atomic level structures became available. Moreover,
appreciation of the key roles played by these receptors
resulted in the development of a wide diversity of ligands able
to either activate or antagonize their function. This was
frequently associated with detailed ligand structure–activity
relationships. As availability and use of tool compounds is
central to all aspects of pharmacology, then this has further
consolidated research focus on amodest number of the GPCR
superfamily. Moreover, becausemodes of activation and regu-
lation of different members of the GPCR family are broadly
similar, much that has been learned from studies on rhodop-
sin and β-adrenoceptors has general relevance to less-studied
receptors. Despite this, subtle variations are likely to be inte-
gral to speciﬁc functions of different family members, and
therefore, it is unwise to assume, as many do, that the most
studied GPCRs provide appropriate answers for drug design
and development at less studied GPCRs. As in many other
areas of target validation, knowledge of GPCR expression pat-
terns, information on phenotypes associated with knock-
down of expression or inactivation of the corresponding gene
and either receptor variant or single nucleotide polymor-
phisms linked to human disease are vital to help prioritize
‘orphan’ or poorly characterized GPCRs as potential
therapeutic targets worthy of detailed study.
GPR35 and FFA2 receptors: two
incompletely understood
metabolite-sensing GPCRs
In recent years, the contribution of foodstuffs, and metabo-
lites derived from them, as GPCR activators and homeostatic
regulators of metabolic and immune function has become
abundantly clear (see Blad et al., 2012, Alvarez-Curto and
Milligan, 2016, Tan et al., 2017 for review). Despite this, a
number of the GPCRs that respond to such ligands and
appear to play key roles in such effects remain poorly or
incompletely characterized. Herein, I will focus on two such
GPCRs, the ‘orphan’ receptor GPR35 (Divorty et al., 2015;
Mackenzie and Milligan, 2017) and the free fatty acid
receptor 2 (FFA2) (Bolognini et al., 2016a; Milligan et al.,
2017a, b), a receptor responsive to short-chain fatty acids
(SCFAs), and suggest why this remains so. This is despite an
FFA2 receptor antagonist already having being assessed in
phase II clinical trials.
FFA2 receptors: opportunities and
challenges
Previously designated GPR43 (Sawzdargo et al., 1997) and de-
orphanized in 2003 as a receptor for propionate and other
SCFAs (Brown et al., 2003), the FFA2 receptor has been
studied extensively (Bolognini et al., 2016a; Milligan et al.,
2017a). In signiﬁcant part, this reﬂects the wide-ranging roles
suggested for SCFAs. These metabolic products are generated
by the microbiota mainly in the lower gut by fermentation of
non-digestible carbohydrates. The integral role that the
microbiota plays in health and disease is a topic of ever
expanding interest. However, for pharmacologists, studying
FFA2 receptors presents many challenges. Although it is clear
that SCFAs are indeed the endogenous activators of this
GPCR, concentrations that induce responses are in the high
μM to low mM range. Moreover, a second receptor, free fatty
acid receptor 3 (FFA3), responds to the same group of SCFAs
(Bolognini et al., 2016a). Although there is a distinct
structure–activity relationship for the SCFAs between the
two receptors, there is insufﬁcient separation to use any indi-
vidual SCFA in an ex vivo or in vivo context to specify with
conﬁdence the receptor involved in a response (Bolognini
et al., 2016a; Milligan et al., 2017b). This is exacerbated
because potencies of the SCFAs differ between human and
rodent orthologues of these receptors. This feature has been
attributed to differences in the potential to form pairs of
extracellular ‘ionic locks’ between conserved arginine
residues that form the core of the orthosteric binding pockets
and negatively charged residues within the second extracellu-
lar loop (Hudson et al., 2012a). Further issues stem from the
close linkage of the genes encoding FFA2 and FFA3 receptors
at chromosome 19q13.1 in human and 7 A3 in mouse.
Indeed, in at least one reported example, knockout of FFA2
receptors in mouse resulted in compensatory up-regulation
of levels of FFA3 receptor mRNA in white adipose tissue
(Bjursell et al., 2011), complicating interpretation of the study
outcomes.
The greatest limitation for pharmacological studies,
however, has been the paucity of selective and pan-species
active FFA2 or FFA3 receptor ligands. Although at least two
series of FFA2 receptor selective, orthosteric agonist ligands
have been reported in the patent literature (Milligan et al.,
2017b), exemplars from these series have, to date, been
employed sparingly in peer-reviewed publications. This is
likely to reﬂect a combination of a remaining caution of
certain pharmaceutical companies to provide such ligands
to the academic community, alongside the often poor links
between academic pharmacologists and medicinal chemists,
which could and should allow synthesis and study of
patented ligands for basic underpinning research. There are,
of course, exceptions to this. 3-Benzyl-4-(cyclopropyl-(4-
(2,5-dichlorophenyl)thiazol-2-yl)amino)-4-oxobutanoic acid
(‘compound 1’ in Hudson et al., 2013), initially exempliﬁed
in a patent from Euroscreen (nowOgeda SA), was synthesized
and used to show the capacity of FFA2 receptors to act both as
anti-lipolytic receptors in model adipocytes of both human
and murine origin (Hudson et al., 2013) and to promote re-
lease of the incretin GLP-1 from the murine enteroendocrine
cell line STC-1 (Hudson et al., 2013). Furthermore, (2S, R5)-5-
(2-chlorophenyl)-1–1(20-methoxy-[1,10-biphenyl]-4carbonyl)
pyrrolidine-2-carboxylic acid (‘compound 1’ in Forbes et al.,
2015), also described initially in a patent from Euroscreen
(Milligan et al., 2017a, b), has been used to show a role of
FFA2 receptors in inhibiting intestinal functions and suppres-
sion of food intake via PYY receptor-mediated pathways in
mice. These highlight means by which pharmacologists may
be able to access patented and, therefore, publically de-
scribed, GPCR-active ligands that are not available from com-
mercial sources.
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In many settings, antagonist ligands can offer wider
opportunities to deﬁne speciﬁc roles for GPCRs. At least three
separate classes of FFA2 receptor antagonists have been
described (Milligan et al., 2017a, b). However, although
exemplars from each series are able to block agonist actions
at human FFA2 receptors, none of them display signiﬁcant
afﬁnity at rodent orthologues of this receptor (Milligan
et al., 2017a, b) (Figure 2). Thus, whilst CATPB was able to
block the anti-lipolytic effect of ‘compound 1’ in human
SW872 adipocytes, it was unable to do so in murine 3T3-L1
cells (Hudson et al., 2013). Equally, whilst GLPG0974 is able
to block acetate-induced chemotaxis of human neutrophils
(Pizzonero et al., 2014), this compound is all but inactive at
rodent orthologues of FFA2 receptors (Pizzonero et al., 2014;
Sergeev et al., 2016) and unable to bind to mouse FFA2 recep-
tors with signiﬁcant afﬁnity (Sergeev et al., 2016).
Despite this challenge, Galapagos NV developed
GLPG0974 for clinical studies using a biomarker for target
engagement in human blood, based on the ability of
GLPG0974 to prevent acetate-induced up-regulation of the
‘activation epitope’ of the integrin CD11b (Pizzonero et al.,
2014). Outcomes of the subsequent early-stage clinical stud-
ies have been reported by Namour et al. (2016), but, sadly,
phase II trials failed to demonstrate efﬁcacy of GLPG0974 in
patients with ulcerative colitis and these trials, therefore,
were terminated. Although a series of rodent disease-model
studies might have been instructive, this was not practical
for GLPG0974 due to the lack of afﬁnity of GLPG0974 at
rodent orthologues of FFA2 (Figure 2). Interestingly Hudson
et al. (2012b) noted that bovine FFA2 receptors responded
optimally to fatty acids of somewhat longer chain length
than do the human or rodent forms. Based on this, and se-
quence alignments, they were able to generate a mutationally
modiﬁed ‘designer receptor exclusively activated by designer
drug’ (DREADD) form of human FFA2 receptor that no longer
responded to the SCFAs acetate or propionate but was
activated instead by a number of non-endogenous ligands,
including sorbic acid (Hudson et al., 2012b). Importantly,
the mutations introduced to develop the DREADD variant
do not interfere with binding of FFA2 receptor antagonists
from either of the described high-afﬁnity series. Notably,
Bolognini et al. (2016a) have highlighted that production of
transgenic mice in which either a humanized form of FFA2
receptors or a humanized form of the DREADD FFA2 receptor
is expressed in place of the mouse orthologue has been
achieved. Although pharmacological studies on these
animals, and tissues derived from them, have not yet been
reported, it is hoped that such studies will shed new light
on the patho-physiological roles of FFA2 receptors and
allow the human-speciﬁc FFA2 receptor antagonists to
block effects of orthosteric agonists and deﬁne potential
‘on-target’ versus ‘off-target’ effects of SCFAs in tissues
derived from these animals, and even potentially directly
in in vivo studies.
FFA2 receptors: orthosteric versus
allosteric agonists
It is often stated that there must be evolutionary pressure to
maintain orthosteric ligand-binding pockets in GPCRs to
avoid loss of function. By contrast, an argument can be made
that this should be less intense for allosteric sites that recog-
nize synthetic compounds to which the receptor has never
naturally been exposed. This does not mean, however, that
allosteric ligands are intrinsically species orthologue selec-
tive. In the case of FFA2 receptors, two key allosteric agonists
have been described. 4-CMTB (Lee et al., 2008; Smith et al.,
2011; Grundmann et al., 2016) and AZ1729 (Bolognini et al.,
2016b) are each able to directly activate both human and
rodent forms of FFA2 receptors and do so via one or more
allosteric sites. AZ1729 is potentially of particular interest to
Figure 2
Mouse and human orthologues of FFA2 receptors display extreme differences in antagonist ligand pharmacology. For both mouse and human
FFA2 receptors, short-chain fatty acids induce activation of a panoply of signals via different members of the family of heterotrimeric G proteins
(see Figure 3). However, antagonists from two reported chemical series, exempliﬁed by GLPG0974 and CATPB, display no signiﬁcant afﬁnity at
mouse FFA2 receptors, although they are high-afﬁnity, orthosteric antagonists at the human FFA2 receptor.
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British Journal of Pharmacology (2017) •• ••–•• 5
pharmacologists as it acts as a highly ‘biased’ agonist. While
SCFAs induce conformations of FFA2 receptors able to inter-
act with both Gi and Gq-family G proteins, AZ1729 is able
to promote signalling only via Gi-mediated mechanisms
(Bolognini et al., 2016b). As such, although AZ1729 is able
to induce anti-lipolytic effects in adipocytes via FFA2 recep-
tors, in a Pertussis toxin-sensitive and, therefore, Gi-mediated
manner, it is unable to promote release of GLP-1 from mouse
colonic crypts. By contrast SCFAs do so, and in a manner that
is instead blocked by the selective Gq/G11 inhibitor
FR900359 (Bolognini et al., 2016b). AZ1729 has, therefore,
been posited to provide a means to determine the contribu-
tion of Gi-G proteins to downstream signal transduction
processes that may coalesce from multiple signalling path-
ways. The best example to date of such a use of AZ1729 has
been to deﬁne the contribution of Gi-family G proteins to
the regulation of ERK1/2 phosphorylation following
expression of species orthologues of FFA2 receptors in
HEK293 cells. For human FFA2 receptors in naïve cells, the
SCFA propionate produces a very robust stimulation of
ERK1/2 phosphorylation, whereas AZ1729 produces only
very limited activation. Following treatment with Pertussis
toxin to inactivate Gi-proteins, the signal induced by
AZ1729 was abolished, whereas responses to propionate
remained robust. By contrast after treatment of cells with
the Gq/G11 inhibitor FR900359, the modest response to
AZ1729 was maintained while the response to propionate
was now as limited, as for AZ1729 (Bolognini et al., 2016b).
This implies that the key transducers of this effect are the
Gq/G11-family proteins (Figure 3). A completely different
pattern was observed, however, for the mouse FFA2 receptor.
Here, equivalent experiments to those described above
showed that activation of ERK1/2 phosphorylation via this
orthologue is transduced almost entirely by the Gi-family G
proteins (Figure 3). Thus, although focus is routinely on
differences in ligand pharmacology at receptor species
orthologues, these results show that selectivity of GPCR-G
protein coupling, as recently considered by Flock et al.
(2017), can be observed, presumably due to differences on
the intracellular, G protein-contact surface of the receptor.
Understanding the molecular basis for such effects and how
they may shape different physiological outcomes in rodent
versus human tissues may be as important in terms of
smoothing the path of medicine development as the more
widely (and wildly) championed concept of ‘ligand bias’.
The characterization and use of AZ1729 (Bolognini et al.,
2016b) is an interesting example of ‘Open Innovation’ poli-
cies, now being adopted more widely by pharmaceutical
companies. Here, both early stage, far from optimized,
ligands but also in some cases clinically trialled molecules,
are being made available to academic researchers to promote
better understanding of underpinning biology and, there-
fore, potential target validation, as part of ‘pre-competitive’
programmes of research. In the example of AZ1729, this
molecule was scored simply as a ‘hit’ in a high-throughput
screen conducted internally by AstraZeneca, and the details
of its mode of action were deﬁned subsequently within an
academic–industrial collaboration.
Figure 3
Species orthologues of FFA2 receptors display G protein selectivity. SCFAs promote phosphorylation and activation of ERK1/2 MAP kinases in
HEK293 cells transfected to express either human or mouse FFA2. However, combinations of studies with the G protein inhibitors Pertussis toxin
(Gi) and FR900359 (Gq/G11) and the Gi-biased FFA2 agonist AZ1729 demonstrate that while activation of the human orthologue transmits this
signal largely via Gq/G11, for the mouse orthologue the signal is transmitted largely via Gi. The indicated size of the noted G protein subtypes il-
lustrates the relative contribution of each to SCFA-mediated activation of ERK1/2 MAP kinases. See text and Bolognini et al. (2016b) for further
details.
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GPR35: opportunities and challenges
GPR35 remains an ‘orphan’ receptor although both
kynurenic acid (Wang et al., 2006) and the chemokine
CXCL17 (Maravillas-Montero et al., 2015) have been pro-
posed as endogenous ligands. CXCL17 has been championed
as a ligand in a single publication and, therefore, requires
independent support from other studies and approaches.
However, whilst Maravillas-Montero et al. (2015) highlighted
structurally conserved features between GPR35 and highly
characterized chemokine receptors, including CXCR7 and
CXCR4, a recent re-stratiﬁcation of class A GPCRs based on
homology within core ligand-binding domains that effec-
tively clustered CXCR7 and CXCR4 and other bona fide
receptors for chemokines placed GPR35 on a completely
separate branch (Ngo et al., 2017). In the case of kynurenic
acid, although it is clear from many publications that this
molecule, which is produced endogenously by metabolism
of the amino acid tryptophan, can activate GPR35 if provided
at sufﬁciently high concentrations, marked variation in
reported potency of kynurenic acid at species orthologues of
the receptor (Milligan, 2011) (Figure 4) has hindered accep-
tance of this metabolite as the true endogenous agonist.
Indeed, potency of kynurenic acid is particularly low at
human GPR35 (Jenkins et al., 2011), and this may exclude a
role for kynurenic acid at human GPR35 (Figure 4).
The potential of targeting GPR35 in a therapeutic context
is supported in part by genetic associations that have
suggested roles in diseases including ulcerative colitis and
primary sclerosing cholangitis (Ellinghaus et al., 2013; Yang
et al., 2015), and GPR35 is highly expressed in regions of,
particularly, the lower gut and colon and by various white cell
groups, including numerous dendritic cell and monocyte
populations. Potential roles for GPR35 in the regulation of
pain have also been supported (Resta et al., 2016; Khan and
He, 2017; Mackenzie and Milligan, 2017) as the receptor in
also expressed regionally in both the central and peripheral
nervous systems.
GPR35: ligand pharmacology and
species variation
Sequence variation between human, rat and mouse
orthologues of GPR35 is substantial (Milligan, 2011). Unsur-
prisingly, therefore, this is manifest in marked variation in
agonist ligand pharmacology. Like FFA2 receptors, this is also
the case for antagonist ligands for GPR35 (Figure 4) and
creates major challenges for pharmacological deﬁnition of
receptor functions. Two series of relatively high afﬁnity
GPR35 antagonists have been reported (Heynen-Genel et al.,
2010, 2011), but, although effective blockers of human
GPR35 (Jenkins et al., 2012), at least following heterologous
expression of rat and mouse GPR35 into HEK293 cells,
neither of the currently commercially available antagonist
ligands, CID-2745687 and ML-145 (Figure 4), are able to
block agonist effects at these orthologues (Jenkins et al.,
2012). It is, therefore, somewhat confusing that ML-145 has
been reported to partially block effects of the GPR35 activator
zaprinast in rat CA1 hippocampal neurons (Alkondon et al.,
Figure 4
Mouse and human orthologues of GPR35 display marked differences in antagonist ligand pharmacology. Although the tryptophan metabolite
kynurenic acid is able to activate GPR35, it is more potent at the mouse orthologue that at either splice variant of the human orthologue. This
has raised questions of its effectiveness as an agonist at GPR35 in human. Exemplars from two chemical series, illustrated as ML-145 and CID-
27455687, have been shown to be high-potency antagonists of human GPR35. However, at least in transfected cell systems, neither appears able
to block agonist actions at mouse GPR35 (Jenkins et al., 2012). However, in certain reports, these ligands have been reported to block effects at
GPR35 in rodent cells and tissue (see text for details). These dichotomies remain to be understood, but improved pharmacological study is likely to
do so. G protein-mediated signalling resulting from activation GPR35 in different cells and tissues can involve both Gα13 and Pertussis toxin-
sensitive members of the Gi-subfamily.
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2015). Clearly, it is possible that in natively expressing
systems, co-expressed proteins that are not present in
HEK293 cells may alter the pharmacology of a GPCR, as is
known for the small group of single transmembrane domain
receptor activity modulating proteins (Gingell et al., 2016;
Hay et al., 2016). However, the structure of ML-145 contains
a central rhodanine fragment, often found in so-called PAINS
(pan-assay interference compounds) (Everett, 2015). Thus, it
is likely that when used in ex vivo preparations, ML-145 will
have a range of ‘off-target’ effects that are unappreciated.
The limited interaction of many academic pharmacologists
with drug discovery experts and medicinal chemists based
in either academia or the pharmaceutical industry raises the
real danger of lack of appreciation of such issues, and an
over-optimistic hope that the commercial availability of vari-
ous compounds, and their described ‘selectivity’ on provider
websites, is valid. Thus, without support from each of orthog-
onal assays, the parallel use of tissue from ‘knockout’ animals,
or the use of as wide a pharmacology as available for a poorly
characterized GPCR, then conclusions as to its physiological
functions should only be considered as interim. Equally,
despite the results of Jenkins et al. (2012) indicating a lack
of action of CID-2745687 at mouse GPR35, CID-2745687
had previously been reported to inhibit agonist-induced
interactions between mouse GPR35 and a form of β-arrestin
2 tagged with a ﬂuorescent protein in HEK293 cells (Zhao
et al., 2010) and, more recently, to inhibit the ability of
kynurenic acid to affect forskolin-mediated regulation of
cAMP levels in mouse astrocytes (Berlinguer-Palmini et al.,
2013) and to block effects of a GPR35 agonist in young adult
mouse colon epithelial cells (Tsukahara et al., 2017). These
results are clearly incompatible with the ﬁndings of Jenkins
et al. (2012), assuming that CID-2745687 was actually acting
via GPR35 in these studies. However, in a more positive
context, in isolated human saphenous vein smooth muscle
cells, GPR35 agonist-induced cell lengthening and cell migra-
tion were both blocked effectively by concentrations of both
CID-2745687 and ML-145 consistent with reports on the
afﬁnity of these ligands at human GPR35, as deﬁned from
in vitro studies (McCallum et al., 2015), as was proliferation
of human saphenous vein endothelial cells (McCallum
et al., 2015).
GPR35: signalling mechanisms
A further challenging feature of GPR35 is the mechanism(s)
this receptor employs for signal transduction. While signal-
ling in a number of, particularly, neuronal preparations
appears to be mediated via one or more Pertussis toxin-
sensitive G proteins (Figure 4) and can regulate levels of cAMP
(Mackenzie and Milligan, 2017), in many other cases, it
appears that key G protein-mediated effects proceed via the
poorly studied G protein Gα13 (Jenkins et al., 2010, 2011).
This has been assessed in experiments measuring agonist-
induced binding of [35S]GTP[S] to an introduced epitope-
tagged form of Gα13 (Jenkins et al., 2010) and in assays
employing a chimeric Gαq/Gα13 G protein that allows
receptor interaction with Gα13 to be converted into elevation
of intracellular Ca2+ levels (Jenkins et al., 2011). Moreover, in
human saphenous vein smooth muscle cells, GPR35 agonist-
induced cell migration is inhibited by each of two mechanis-
tically distinct Rho-kinase inhibitors (McCallum et al., 2015).
Although activation of Gα13 does not directly regulate levels
of secondary messengers, it does regulate Rho-guanine nucle-
otide exchange factors. In some of the earliest detailed
studies, chimeric G proteins based on the backbone of the α
subunit of the Saccharomyces cerevisiae G protein Gpa1
(Jenkins et al., 2010) or the mammalian G protein Gq (Jenkins
et al., 2011) were used to show effective coupling of GPR35 to
Gα13, and that this was the case for both human and rat
GPR35 (Jenkins et al., 2011). Although G13 is often viewed
as being functionally equivalent to the related G protein
G12, this is unlikely to be the case as both genes have been
preserved across species, and mouse gene ‘knockout’ studies
conﬁrm that they are non-redundant, with lack of only
Gα13 resulting in early embryonic lethality linked to a lack
of angiogenesis (Worzfeld et al., 2008). Indeed, in parallel
studies, whilst a Gq-Gα13 chimeric G protein was able to link
both human and rat GPR35 to elevation of intracellular
Ca2+ levels, an equivalent Gq-Gα12 chimera was only very
weakly active, whilst full length Gαq was entirely without
function (Jenkins et al., 2011).
In part, because selective activation of Gα13 is highly
challenging to assess in any high-throughput assay format,
efforts to identify novel agonists of GPR35 have focussed on
either the use of ‘dynamic mass redistribution’ studies,
performed almost exclusively using the human HT29 adeno-
carcinoma cell line (e.g. Wei et al., 2017) that expresses
GPR35 endogenously but where the mode of signalling is
undeﬁned, or various assay formats that measure induced
translocation and interaction with the receptor, of forms of
β-arrestin (Zhao et al., 2010; Jenkins et al., 2011; Funke et al.,
2013; Neetoo-Isseljee et al., 2013; MacKenzie et al., 2014).
Where tested, these have conﬁrmed that many GPR35
agonists display marked species-dependent variation in
potency (Figure 1), but a number of molecules, including
pamoic acid, lodoxamide and ligands based on 8-amido-
chromen-4-one-2-carboxylic acid, that display high potency
at one or more species orthologue (usually human) have been
identiﬁed (Divorty et al., 2015). However, as discussed earlier
for the antagonist ML-145, a number of these ligands are
appreciated to have othermolecular targets, with pamoic acid
identiﬁed initially as a GPR35 agonist because pamoate was
the common feature in a number of compound preparations
that appeared as active at GPR35 but without other obvious
common chemical signatures (Jenkins et al., 2010, Zhao
et al., 2010, see Neubig, 2010 for review). This is akin to the
de-orphanization of FFA2 receptors (Brown et al., 2003),
where the common feature of apparent hits was that
they were all tested initially as acetate salts. The focus on
using β-arrestin-based assays in identiﬁcation of ligands may
result in the prioritization of β-arrestin-‘biased’ agonists, but
this issue has not been assessed directly, potentially once
more due to the challenges of developing robust G protein-
dependent assays for GPR35. To date, only one publication
has described the development and use of a radiolabelled
ligand to identify and characterize the pharmacology of
GPR35. [3H]PSB-13253 (6-bromo-8-(4-methoxybenzamido)-
4-oxo-4H-chromene-2-carboxylic acid) (Thimm et al., 2013)
displayed high afﬁnity (Kd = 5 nM at human GPR35). As the
parent compound is a markedly selective agonist for human
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GPR35 compared to rat or mouse (Funke et al., 2013) then,
although not explored extensively by Thimm et al. (2013), it
is unlikely to be useful to study rodent orthologues of
GPR35. Moreover, all the studies reported by Thimm et al.
(2013) were performed using membrane preparations from
CHO cells expressing very high levels of human GPR35,
estimated to be in the region of 12 pmol·mg1 membrane
protein. It remains to be established if [3H]PSB-13253 can be
used to detect and study the pharmacological proﬁle of
human GPR35 in cells or tissues that express the receptor
endogenously. As with FFA2 receptors, it may be that trans-
genic mice expressing a humanized version of GPR35 could
provide an effective means of helping to better deﬁne
potential therapeutic roles for ligands at GPR35. However,
given the relative dissimilarity of mouse and human GPR35
sequences then, as noted above for FFA2 receptors, despite
the evidence to date that suggests that both human and
rodent forms of GPR35 show marked selectivity in coupling
to Gα13, it is possible that G protein engagement patterns will
vary between orthologues and result in distinct downstream
signalling outcomes.
A further challenge on how to interpret data from GPR35
studies in animal models for its likely effects on the therapeu-
tic opportunities offered by GPR35 in the treatment of
human disease is that, although both rat and mouse express
a single form of the receptor, there are two forms in human.
The short isoform corresponds to the rodent orthologue,
but there is also an N-terminally extended splice variant that
incorporates an additional 31 amino acids into this region
of the receptor (Milligan, 2011). Although there is little
evidence to date of distinct pharmacology between the
human short (GPR35a) and long (GPR35b) variants, it may
be that these will differ in details of localization as is the case,
for example, for the GABAB1a and GABAB1b isoforms of the
GABAB1 receptor.
Conclusions
It can be argued that the key focus to date on GPCRs that are
activated by biogenic amines simply reﬂects the highmedical
importance and prevalence of diseases that are associated
with dysregulation of these ancient regulators of a broad raft
of physiological processes. However, as pharmacological
studies are entirely reliant on access to high-quality and
well-characterized tool compounds, this focus has
become something of a self-fulﬁlling tradition. Progress in
understanding less well-characterized GPCRs will require
combinations of yet greater willingness of companies to offer
access to tool compounds. It is also vital that academic
pharmacologists interact much more closely with medicinal
chemists in both the academic and industrial spheres to make
better use of the plethora of novel ligands described within
the patent literature, and for pharmacologists to be far more
discerning in selecting, or further characterizing, ligands to
ensure they are ﬁt for purpose and truly display the selectivity
or speciﬁcity attributed to them. With these basic tenets in
place, the potential for much more convincing target valida-
tion of GPCRs that are ‘not currently in the spotlight’ will
be greatly enhanced to the beneﬁt of pharmacologists, the
pharmaceutical industry and ultimately, patients.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked
to corresponding entries in http://www.guidetopharma
cology.org, the common portal for data from the
IUPHAR/BPS Guide to PHARMACOLOGY (Southan et al.,
2016), and are permanently archived in the Concise Guide
to PHARMACOLOGY 2015/16 (Alexander et al., 2015a, b, c).
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